HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Mulls More Onerous Cosmetics Reclassification

This article was originally published in The Rose Sheet

Executive Summary

A China proposal to re-categorize some cosmetics products as “special use” could require more than 50,000 products to follow a more lengthy licensing, registration process. Industry in Asia recently addressed concerns in letter to Chinese officials.

You may also be interested in...



Korea Can Serve As “Market Laboratory” For Beauty Firms In Asia

U.S.-based brands including Procter & Gamble and L’Oreal are leveraging the wealth and trend-setting influence of residents of South Korean capital Seoul to test new personal care products.

“Stronger, Wiser” Cosmetics Industry Has Emerged From Recent Turmoil – Council Chair Brestle

The Personal Care Products Council will continue efforts in support of legislation to strengthen FDA oversight without subjecting manufacturers to unnecessary burdens, the trade group’s leadership indicated at the annual meeting in Naples, Fla. Outgoing Chairman Dan Brestle says industry has emerged from recent battles “stronger, wiser and more fiscally sound.”

Pao Principle CEO On Marketing Beauty To Status-Conscious Chinese Consumer

Everyone wants a piece of the $12.5 billion Chinese beauty market, but success in a market where brand loyalty is rare, makeup on minors is taboo and cosmetics in general are a new concept to many, takes savvy and a willingness to invest.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel